Vir Bio Lands Gilead Collaboration With $90M Upfront and $25M Equity at 30% Premium
VIR has more than doubled off its 52-week low of $4.815.
Summary
Vir Biotechnology and Gilead Sciences entered a global collaboration to develop three novel PRO-XTEN dual-masked T-cell engagers for solid tumors, with $90 million upfront ($65M cash + $25M equity at a 30% premium) and up to $1.74 billion in milestones.
Key Events · M&A and Partnerships · VIR
-
Gilead Collaboration Signed
Vir Bio and Gilead entered a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager candidates targeting selected solid tumor-associated antigens.
-
$90M Upfront Consideration
Vir Bio receives $90 million upfront — $65 million in cash plus a $25 million equity investment at $14.16 per share, representing a 30% premium to the stock's recent trading range.
-
Up to $1.74B in Milestones
Vir Bio is eligible for up to $45 million in near-term preclinical milestones and up to $1.74 billion in further development, regulatory, and commercial milestones, plus tiered high single-digit to low double-digit royalties on net sales.
-
Equity Investment Terms
Gilead agreed to purchase 1,765,486 shares at $14.16 per share (~$25 million) under a Stock Purchase Agreement with standstill, voting, and lockup provisions expiring one year after closing.
Analysis · VIR · Life Sciences
Vir Biotechnology signed a multi-program collaboration with Gilead Sciences to discover and develop three novel PRO-XTEN dual-masked T-cell engagers for solid tumors. The deal brings $90 million in upfront consideration — $65 million in cash plus a $25 million equity investment at $14.16 per share, a 30% premium to the stock's recent trading range. Vir Bio is also eligible for up to $45 million in near-term preclinical milestones and up to $1.74 billion in development, regulatory, and commercial milestones, plus tiered royalties. This is the company's second collaboration built on the PRO-XTEN masking platform, validating the technology and providing non-dilutive capital that extends an already strong $1.01 billion cash position.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 38.8% of the 970 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VIR was trading at $11.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $4.82 to $12.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.